PITPNM1

Across TCGA pan-cancer cohorts, PITPNM1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PITPNM1 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PITPNM1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PITPNM1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PITPNM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.637	0.936	.002	87	view →
LUAD	OS	Tertile	II,III,IV	0.357	0.837	.004	17	view →
CCRCC	DFS	Median	III,IV	0.588	0.811	.026	3	view →
HNSC	DFS	Tertile	IV	0.851	0.558	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PITPNM1–PDAC (DFS)

Open the PDAC breakdown →